With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.166330-10-5,(Oxybis(2,1-phenylene))bis(diphenylphosphine),as a common compound, the synthetic route is as follows.
Compound 8 (5.0 g, 9.3 mmol) was melted in 100 mL of CH2C12, and H2O2 (30 percent, 4.0 mL, 186 mmol) was dropped therein while the mixture was being ice bathed. This mixture was stirred for 4 hours. The reactant was quenched with distilled water after stirring, and CH2C12 extraction was performed 3 times. An organic layer was dried with anhydrous magnesium sulfate, and the solvent was distilled off. An obtained solid was purified by a reprecipitation method with use of hexane, which yielded a compound 9 (white powder, 5.0 g, 94 percent). IR (ATR) 1183 (st, P=O), 1070-1226 (st, C-O-C) cm-1 1H NMR (300 MHz, CDCl3, 25 ¡ãC) 87.06-7.71 (m, 26H, Ar), 6.02-6.07 (m, 2H, Ar) ppm 31P NMR (200 MHz, CDCl3, 25 ¡ãC) 826.41 (2P) ppm FAB-Mass(m/z) = 571 [M+H]+., 166330-10-5
As the paragraph descriping shows that 166330-10-5 is playing an increasingly important role.
Reference£º
Patent; National University Corporation Nara Institute of Science and Technology; EP2471799; (2012); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate